These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23521022)

  • 1. Impact of lower urinary tract symptoms on prostate cancer risk among Japanese men with prostate-specific antigen <10 ng/mL and non-suspicious digital rectal examination.
    Ito M; Masuda H; Kawakami S; Fujii Y; Koga F; Saito K; Yamamoto S; Yonese J; Fukui I; Kihara K
    Int J Urol; 2013 Dec; 20(12):1163-8. PubMed ID: 23521022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA ≥3 ng/ml.
    Chandra Engel J; Palsdottir T; Aly M; Egevad L; Grönberg H; Eklund M; Nordström T
    Scand J Urol; 2020 Feb; 54(1):1-6. PubMed ID: 31876229
    [No Abstract]   [Full Text] [Related]  

  • 3. Body mass index influences prostate cancer risk at biopsy in Japanese men.
    Masuda H; Kagawa M; Kawakami S; Numao N; Matsuoka Y; Yokoyama M; Yamamoto S; Yonese J; Fukui I; Kihara K
    Int J Urol; 2013 Jul; 20(7):701-7. PubMed ID: 23186107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative probability of prostate cancer detection using the international prostate symptom score in a prostate-specific antigen-based population screening program in Japan.
    Kitagawa Y; Urata S; Narimoto K; Nakagawa T; Izumi K; Kadono Y; Konaka H; Mizokami A; Namiki M
    Asian Pac J Cancer Prev; 2014; 15(17):7079-83. PubMed ID: 25227794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second to fourth digit ratio: its relationship with core cancer volume and Gleason score in prostate biopsy.
    Oh JK; Kim KH; Jung H; Yoon SJ; Kim TB
    Int Braz J Urol; 2012; 38(5):611-9. PubMed ID: 23131519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer.
    Halpern JA; Oromendia C; Shoag JE; Mittal S; Cosiano MF; Ballman KV; Vickers AJ; Hu JC
    J Urol; 2018 Apr; 199(4):947-953. PubMed ID: 29061540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/mL equivalent to that in men with 4.1 to 10.0 ng/mL in a Japanese population.
    Kobayashi T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    Urology; 2004 Apr; 63(4):727-31. PubMed ID: 15072889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.
    Lee A; Lim J; Gao X; Liu L; Chia SJ
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e348-e355. PubMed ID: 27641069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate Volume Index Is Able to Differentiate between Prostatic Chronic Inflammation and Prostate Cancer in Patients with Normal Digital Rectal Examination and Prostate-Specific Antigen Values <10 ng/mL: Results of 564 Biopsy Naïve Cases.
    Porcaro AB; Tafuri A; Sebben M; Novella G; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Panunzio A; De Michele M; Brunelli M; Cerruto MA; Migliorini F; Siracusano S; Artibani W
    Urol Int; 2019; 103(4):415-422. PubMed ID: 31466070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
    Goldberg H; Klaassen Z; Chandrasekar T; Wallis CJD; Toi A; Sayyid R; Bhindi B; Nesbitt M; Evans A; van der Kwast T; Sweet J; Perlis N; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta A; Fleshner N
    J Urol; 2018 Nov; 200(5):1056-1061. PubMed ID: 29758220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
    Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).
    Chen R; Zhou LQ; Cai XB; Xie LP; Huang YR; He DL; Gao X; Xu CL; Ding Q; Wei Q; Yin CJ; Ren SC; Wang FB; Tian Y; Sun ZQ; Fu Q; Ma LL; Zheng JH; Ye ZQ; Ye DW; Xu DF; Hou JQ; Xu KX; Yuan JL; Gao X; Liu CX; Pan TJ; Sun YH;
    Asian J Androl; 2015; 17(6):1017-21. PubMed ID: 25926603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower urinary tract symptoms and risk of prostate cancer in Japanese men.
    Matsubara A; Yasumoto H; Teishima J; Seki M; Mita K; Hasegawa Y; Yoshino T; Kato M; Usui T
    Int J Urol; 2006 Aug; 13(8):1098-102. PubMed ID: 16903936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial.
    Frånlund M; Carlsson S; Stranne J; Aus G; Hugosson J
    BJU Int; 2012 Sep; 110(5):638-43. PubMed ID: 22540895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.
    Mason M; Maldonado Pijoan X; Steidle C; Guerif S; Wiegel T; van der Meulen E; Bergqvist PB; Khoo V
    Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):190-6. PubMed ID: 23257248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
    Antunes AA; Srougi M; Dall'oglio MF; Vicentini F; Paranhos M; Freire GC
    J Sex Med; 2008 Jul; 5(7):1702-7. PubMed ID: 18194186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.
    Ochiai A; Okihara K; Kamoi K; Oikawa T; Shimazui T; Murayama S; Tomita K; Umekawa T; Uemura H; Miki T
    BJU Int; 2013 May; 111(6):928-33. PubMed ID: 23331404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
    Braun K; Sjoberg DD; Vickers AJ; Lilja H; Bjartell AS
    Eur Urol; 2016 Mar; 69(3):505-11. PubMed ID: 25979570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of lower urinary tract symptoms is an independent predictor for cancer at prostate biopsy, but prostate-specific antigen is not: results from a prospective series of 569 patients.
    Porter CR; Latchamsetty KC; Coogan CL; Kim J
    Clin Prostate Cancer; 2005 Jun; 4(1):50-4. PubMed ID: 15992462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.